Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

Colorectal Cancer Clinical Trial

Official title:

A Phase II Study of Rebeccamycin Analogue NSC 655649 in Patients With Metastatic Colorectal Cancer (IMT Codes 23988, 23989, 23993)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00005085
• Other study ID #: CDR0000067695
• Secondary ID: AECM-T99-0109NCI
• Status: Completed
• Phase: Phase 2
• First received: April 6, 2000
• Last updated: February 8, 2013
• Start date: February 2000

Study information

• Verified date: December 2002
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Phase II trial to study the effectiveness of rebeccamycin analog in treating patients who have metastatic or locally recurrent colorectal cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Description:

OBJECTIVES:

I. Determine the objective response rate of patients with metastatic or locally recurrent colorectal cancer treated with rebeccamycin analogue.

II. Determine the toxicity of this regimen in this patient population. III. Determine the effect of this regimen on progression-free and overall survival in these patients.

OUTLINE: This is a multicenter study.

Patients receive rebeccamycin analogue IV once on day 1. Treatment repeats every 21 days for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. primary completion date: June 2002
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed metastatic or locally recurrent adenocarcinoma of the colon or rectum

• No curable stage of disease

• At least 1 unidimensionally measurable lesion

• At 20 mm by conventional techniques OR at least 10 mm by spiral CT scan

• No tumor lesions in previously irradiated area except clearly measurable lesion documented histologically to be consistent with recurrent tumor in previously irradiated bed within pelvis

• The following are considered nonmeasurable disease:

• Bone lesions Leptomeningeal disease

• Ascites

• Pleural/pericardial effusion

• Inflammatory breast disease

• Lymphangitis cutis/pulmonis

• Abdominal masses not confirmed and followed by imaging techniques

• Cystic lesions

• No known brain metastases

PATIENT CHARACTERISTICS:

• Age: 18 and over

• Performance status: ECOG 0-2 OR Karnofsky 60-100%

• Life expectancy: More than 12 weeks

• WBC at least 3,000/mm3

• Absolute neutrophil count at least 1,500/mm3

• Platelet count at least 100,000/mm3

• Bilirubin normal

• AST/ALT no greater than 2.5 times upper limit of normal

• Creatinine normal OR creatinine clearance at least 60 mL/min

• No symptomatic congestive heart failure

• No unstable angina pectoris

• No cardiac arrhythmia

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception during and for 6 months after study

• Eligible for placement of a central venous catheter

• No prior allergic reactions attributed to compounds of similar chemical or biologic composition to rebeccamycin analogue

• No other uncontrolled concurrent illness

• No ongoing or active infection

• No psychiatric illness or social situation that would preclude study compliance

PRIOR CONCURRENT THERAPY:

• No concurrent prophylactic growth factors (e.g., epoetin alfa) except for clinically defined indication (e.g., filgrastim (G-CSF) for febrile neutropenia)

• At least 4 weeks since prior chemotherapy (e.g., fluorouracil, oral fluoropyrimidines, irinotecan, or oxaliplatin) (6 weeks for nitrosoureas or mitomycin)

• No other concurrent chemotherapy

• No concurrent hormones except for clinically defined indication

• At least 4 weeks since prior radiotherapy (including to bony sites, whole pelvis, lung, liver, or spinal cord/brain) and recovered

• No prior total dose of radiotherapy more than 7,000 cGy

• No prior radiotherapy to 40% or more of total bone marrow

• No prior radiotherapy to only site of measurable disease

• No concurrent radiotherapy

• Recovered from prior therapy 1 prior adjuvant treatment allowed 1 prior treatment for advanced disease allowed

• At least 4 weeks since prior investigational agents

• No other concurrent investigational antineoplastic drugs

• No other concurrent investigational agents

• No concurrent commercial agents for colorectal cancer

• No concurrent combination antiretroviral therapy for HIV-positive patients

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Drug:
• becatecarin

Locations

Country	Name	City	State
United States	Atlanta Cancer Care	Atlanta	Georgia
United States	Albert Einstein Comprehensive Cancer Center	Bronx	New York
United States	New York Medical College	Valhalla	New York

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States,